Semaglutide, the active ingredient in Ozempic and Wegovy, is a glucagon-like peptide-1 (GLP-1) receptor agonist taken as a once-weekly injection. It's administered with a tiny needle that punctures ...
This article was reviewed by Craig Primack, MD, FACP, FAAP, FOMA. Semaglutide, the active ingredient in Ozempic and Wegovy, is a glucagon-like peptide-1 (GLP-1) receptor agonist taken as a once-weekly ...
The first generic weight-loss GLP-1 injection Sevmia was recently approved by Health Canada. Here’s what you need to know.
WESTON, Fla., April 10, 2026 /PRNewswire/ - Apotex Corp. today announced it has received the first U.S. Food and Drug Administration (FDA) Tentative Approval for its Abbreviated New Drug Application ...
The arrival of generic semaglutide in India was expected to make obesity and diabetes treatment more affordable and ...
Novo Nordisk will launch its authorised semaglutide copy in South Africa on 27 July, offering a lower-cost alternative to ...
Novo Nordisk South Africa is set to launch an authorised, more affordable version of semaglutide, aimed at improving access ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results